Skip to main content

Market Overview

Recap: Strongbridge Biopharma Q1 Earnings

Share:

 

Shares of Strongbridge Biopharma (NASDAQ:SBBP) fell 3.7% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share rose 42.11% over the past year to ($0.11), which missed the estimate of ($0.10).

Revenue of $8,382,000 rose by 25.59% year over year, which beat the estimate of $8,310,000.

Guidance

Strongbridge Biopharma reaffirmed FY21 KEVEYIS sales guidance of $34 million-$36 million.

How To Listen To The Conference Call

Date: May 12, 2021

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/ifdaytxi

Technicals

Company's 52-week high was at $4.63

Company's 52-week low was at $1.87

Price action over last quarter: down 16.25%

Company Overview

Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.

 

Related Articles (SBBP)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com